While SEC-MALS with a DAWN or miniDAWN is the primary means of characterizing soluble protein aggregates, FFF-MALS, CG-MALS and DLS are valuable orthogonal techniques to meet FDA requirements.
SEC or FFF plus triple detection UV-MALS-RI and ASTRA software determine the molar mass of protein and modifier in conjugated biotherapeutics such as antibody-drug conjugates or PEGylated proteins.
The DynaPro Plate Reader II performs high-throughput screening of excipients and buffers for optimal formulation in situ in standard microwell plates, detecting aggregation as well as conformational and colloidal stability indicators.
CG-MALS combines a Calypso II and DAWN or miniDAWN to characterize the affinity and absolute molecular stoichiometry of drug-target binding, without labeling or immobilization. It also analyzes self-association at low, moderate and high concentrations.